FDA-cleared profile

Spectral Bone Marrow

GE Medical Systems, LLC · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Automatically segments bone to optimize visualization of bone marrow in spectral body and extremity CT for review of traumatic and non-traumatic bone pathologies.

Clinical role
Fully automated deep-learning bone segmentation on spectral body and extremity CT that overlays colored material density images on monochromatic or virtual unenhanced images and sends them as DICOM secondary captures to PACS for review of bone pathologies.
Images and patients
CT/CTA · Bone and bone marrow in body and extremity studies
Key limitation
Keep in mind: Use is limited to the stated spectral body/extremity CT and bone-pathology review; broader protocol and scanner support were not established.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatically segments bone to optimize visualization of bone marrow in spectral body and extremity CT for review of traumatic and non-traumatic bone pathologies.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Bone and bone marrow in body and extremity studies Input: Dual-energy DICOM spectral CT images.
  • Who uses it?Intended users: Clinicians.
  • What does the software produce?Output: Colored Water(HAP) material-density images fused with monochromatic or VUE CT images as secondary-capture DICOM series.
  • What is its most important limitation?Key limitation: Use is limited to the stated spectral body/extremity CT and bone-pathology review; broader protocol and scanner support were not established.

Clinical takeaway. Clinical role: Automatically segments bone to optimize visualization of bone marrow in spectral body and extremity CT for review of traumatic and non-traumatic bone pathologies.

Evidence takeaway. Evidence from the reviewed source record: FDA reported engineering testing on 146 retrospective spectral CT series and a representative clinical image assessment; no numeric sensitivity or specificity was reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatically segments bone to optimize visualization of bone marrow in spectral body and extremity CT for review of traumatic and non-traumatic bone pathologies.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Fully automated deep-learning bone segmentation on spectral body and extremity CT that overlays colored material density images on monochromatic or virtual unenhanced images and sends them as DICOM secondary captures to PACS for review of bone pathologies.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "utilizing deep learning technology for bone segmentation, to facilitate optimized visualization of bone marrow in spectral body and extremity CT images. Spectral Bone Marrow’s output can be used during the review of traumatic and non-traumatic bone pathologies." … "application outputs the colored Water(HAP) material density images overlayed on monochromatic CT images or Virtual Unenhanced (VUE) images.". Read from the exact FDA decision document on 2026-11-14.

Required input
Dual-energy DICOM spectral CT images.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input scope.

Output and clinician action
Colored Water(HAP) material-density images fused with monochromatic or VUE CT images as secondary-capture DICOM series.
  • Exact FDA submission
  • Checked 2026-09-15

FDA output description.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Clinicians.
  • Exact FDA submission
  • Checked 2026-09-15

Narrower credential was not established by the packet.

Limitations
Use is limited to the stated spectral body/extremity CT and bone-pathology review; broader protocol and scanner support were not established.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA scope boundary.

Evidence summary
FDA reported engineering testing on 146 retrospective spectral CT series and a representative clinical image assessment; no numeric sensitivity or specificity was reported.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet evidence summary.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA reported engineering testing on 146 retrospective spectral CT series and a representative clinical image assessment; no numeric sensitivity or specificity was reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet evidence summary.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Spectral Bone Marrow regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K223514
  • IndependenceIndependence not established

K223514

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223514. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Dual-energy DICOM spectral CT images.

    Scope: Exact FDA submission. Exact FDA input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K223514: Spectral Bone Marrow

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · Spectral Bone Marrow model card (K223514)

  3. AI processing

    Source context, not route validation: The exact FDA package describes the software as hosted on GE's Edison Health Link (EHL) computational platform, with a listed deployment environment of CT Console and Edison Health Link (EHL). Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software provides multiplanar export of the fused images. Spectral Bone Marrow is hosted on GE’s Edison Health Link (EHL) computational platform." … "Deployment CT Console, AW Workstation CT Console, Edison Health Link (EHL)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K223514: Spectral Bone Marrow

  4. Returned objects

    Source context, not route validation: Colored Water(HAP) material-density images fused with monochromatic or VUE CT images as secondary-capture DICOM series.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K223514: Spectral Bone Marrow

  5. Viewer/worklist/report

    Unresolved route: Colored Water(HAP) material-density images fused with monochromatic or VUE CT images as secondary-capture DICOM series.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K223514: Spectral Bone Marrow

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the software as hosted on GE's Edison Health Link (EHL) computational platform, with a listed deployment environment of CT Console and Edison Health Link (EHL). Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software provides multiplanar export of the fused images. Spectral Bone Marrow is hosted on GE’s Edison Health Link (EHL) computational platform." … "Deployment CT Console, AW Workstation CT Console, Edison Health Link (EHL)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Monitoring
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Spectral Bone Marrow; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223514
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Spectral dual-energy CT normalized to the controlled CT/CTA bucket; CTA is not implied.

Anatomy
Bone and bone marrow in body and extremity studies
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA anatomy scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-03-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K223514 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K223514: Spectral Bone Marrow

    U.S. Food and Drug Administration - Published 2023-03-09 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Spectral Bone Marrow model card (K223514)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223514

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K223514 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11
FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252103

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software provides modular image processing, visualization, segmentation, measurement, treatment planning, and three-dimensional-printing support; Acorn Trajectory Automation plans pedicle-screw trajectories in adult and pediatric thoracic and lumbar spine cases.

Modality
CT/CTA
Anatomy
Thoracic and lumbar spine, musculoskeletal, craniomaxillofacial, and vascular anatomy
Decision
2025-12-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history